2cureX AB (publ) (STO:2CUREX)

Market Cap	51.56M +1.2%
Revenue (ttm)	1.98M -49.7%
Net Income	-26.35M
EPS	-1.50
Shares Out	31.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,741
Open	1.616
Previous Close	1.616
Day's Range	1.614 - 1.616
52-Week Range	0.514 - 4.200
Beta	3.01
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About 2cureX AB

2cureX AB (publ) operates as a medical technology company in Europe. ts proprietary IndiTreat test family creates various three-dimensional tumoroids derived from fresh samples of colorectal cancer (CRC) tissue that has been obtained from an individual patient’s metastatic colorectal cancer. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 14
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: 2CUREX

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 13, 2026

Data Sources Report a data error